|
|
Screening of preparation process of breviscapine solid dispersion#br# |
TANG Ting LI Fuyuan LIU Yan QIU Yanming |
College of Pharmacy, Hunan Traditional Chinese Medicine College, Hunan Province, Zhuzhou 412000, China |
|
|
Abstract Objective To optimize the preparation process of breviscapine solid dispersion and determine its dissolution in vitro and content. Methods Taking the cumulative dissolution rate as the index, the best carrier and preparation method for preparing solid dispersion were selected through single factor test; the optimal ratio of drug and carrier material was investigated; the optimum preparation process of breviscapine solid dispersion was selected by orthogonal test; the reproducibility, dissolution, and content were investigated. Results The best preparation carrier of breviscapine solid dispersion was poloxamer 188; the best preparation method was melting method; the best preparation process of breviscapine solid dispersion was as follows: the ratio of drug to carrier material was 1∶5, the melting temperature was 70℃, and the cooling temperature was 20℃. Conclusion Breviscapine solid dispersion can improve its solubility.
|
|
|
|
|
[1] 李凤英,曹锦江,李海华,等.中药灯盏花素新制剂的研究进展[J].临床合理用药杂志,2015,8(16):180-181.
[2] 鄂瑞芳,赵琨,赵日光,等.灯盏花素注射液联合阿加曲班治疗急性脑梗死的临床研究[J].现代药物与临床,2021, 36(10):2136-2140.
[3] 刘维,贺承健,张剑锋.灯盏花素对创伤性损伤大鼠的神经保护作用[J].中国公共卫生,2021,37(7):1129-1133.
[4] 卢静怡.灯盏花素加运动抑制脑卒中后神经元自噬的作用机制研究[D].昆明:云南中医药大学,2021.
[5] 王娓娓,叶宏,孙林,等.灯盏花素促进缺血/再灌注损伤的微血管内皮细胞自噬、抑制氧化损伤及凋亡[J].中国药理学通报,2021,37(7):946-951.
[6] 姜明照.灯盏花素对脑缺血再灌注损伤大鼠肠道菌群、TLR4/NF-κB信号通路及肠CYP3A4的影响[D].大理:大理大学,2021.
[7] 李军,吴立友,王朝阳.灯盏花素注射液对2型糖尿病早期肾病患者相关炎症因子的影响[J].中药药理与临床,2011,27(3):110-112.
[8] 陈鹏,崔佳丽,周艺佳,等.灯盏花素口崩片在Beagle犬体内的药动学及相对生物利用度研究[J].云南化工,2021, 48(3):19-22.
[9] 罗玲.灯盏花素固体分散体的研究[D].武汉:中南民族大学,2018.
[10] 解仲伯,李远达,林华庆,等.新型载体Soluplus?誖制备灯盏花素固体分散体及其体外溶出行为研究与表征[J].中国新药杂志,2018,27(5):566-573.
[11] 解仲伯.新型载体Soluplus?誖在灯盏花素固体分散体制备中的应用研究[D].广州:广东药科大学,2017.
[12] 刘柳毅,黄德恩,李庆国.灯盏花素固体分散体缓释片的制备及其体外释药特性考察[J].中国药房,2016,27(4):531-533.
[13] 陈国广,张柯萍,李学明,等.灯盏花素缓释固体分散体的制备及溶出度的研究[J].华西药学杂志,2007,22(2):169-171.
[14] 钟海军,邓英杰.灯盏花素新剂型研究进展[J].中成药,2005,27(8):950-953.
[15] 国家药典委员会.中华人民共和国药典[S].四部.北京:中国医药科技出版社,2020.
[16] 巴娟.替米考星固体分散体的制备及在猪体内的药动学研究[D].佛山:佛山科学技术学院,2019.
[17] 胡均鹏.高水溶性叶黄素固体分散体的制备[D].广州:华南理工大学,2019.
[18] 王众勤.硫酸氢氯吡格雷固体分散体制备和体外评价[D].上海:上海交通大学,2019.
[19] 刘莹莹.人参发酵产物固体分散体的制备及质量评价[D].长春:长春中医药大学,2019.
[20] 金刚,王洁,彭蕾,等.三种方法制备吉非罗齐固体分散体的性质比较[J].吉林化工学院学报,2019,36(11):12-16.
[21] 武磊.抗癌药乐伐替尼的合成研究及其固体分散体的制备[D].武汉:武汉工程大学,2019.
[22] 古丽巴哈尔·卡吾力,常占瑛,谢湘云,等.黑果枸杞总黄酮固体分散体的制备[J].食品工业科技,2018,39(23):182-187.
[23] 吴均成.HPLC法测定灯盏花素葡萄糖注射中5-羟甲基糠醛的含量及限度修订[J].亚太传统医药,2020,16(9):47-50. |
|
|
|